Skip to main content

US ClosedU.S. Closed

KLRA: Kailera Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

52W Range

8thpctl

Volume

0.77×avg

Market Cap

2.10BUSD

P/E Ratio

-9.2TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

Kailera Therapeutics, Inc.

KLRANASDAQ Global Select·USD·Closed

Kailera Therapeutics, Inc.

KLRANASDAQ·USD·Closed

$16.23

+3.11%

$16.23

+$0.49 (3.11%)

52W Range

8thpctl

Volume

0.77×avg

Mkt Cap

2.10BUSD

P/E

-9.2TTM

Div Yield

–ann